v3.26.3
Sale of Future Revenue - Narrative (Details) - USD ($)
$ in Thousands
2 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 71 Months Ended
Nov. 03, 2020
Dec. 31, 2020
Sep. 30, 2026
Sep. 30, 2025
Jun. 30, 2020
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Sep. 30, 2026
Disaggregation of Revenue [Line Items]                  
Payments for financing costs           $ 4,100 $ 0    
Revenues     $ 7,557 $ 12,807   35,822 $ 31,530    
Royalty                  
Disaggregation of Revenue [Line Items]                  
Revenues           1,013   $ 938  
MAM Pangolin Royalty , LLC | Maximum                  
Disaggregation of Revenue [Line Items]                  
Proceeds from sale of future revenue $ 125,000                
License agreement with Sunovion Pharmaceuticals, Inc.                  
Disaggregation of Revenue [Line Items]                  
Minimum annual royalty receivable     1,000   $ 1,000 $ 1,000     $ 1,000
License agreement with Sunovion Pharmaceuticals, Inc. | Royalty                  
Disaggregation of Revenue [Line Items]                  
Revenues         $ 8,000        
Monetization Agreement                  
Disaggregation of Revenue [Line Items]                  
Payments for financing costs     $ 2,909            
Effective annual interest rate (as a percent) 24.90%                
Monetization Agreement | MAM Pangolin Royalty , LLC                  
Disaggregation of Revenue [Line Items]                  
Proceeds from sale of future revenue $ 40,000 $ 10,000             $ 50,000
Proceeds from debt, contingent on additional milestones $ 75,000